Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Gotkine

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Biomed Research International|January 24, 2014
Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) miceMarc Gotkine, Gotkine Marc, Leah Rozenstein, et al.
Muscle & Nerve|December 12, 2013
Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapyPanayiota Petrou, Avizohar Argov, Vanda A Lennon, et al.
JAMA Neurology|January 12, 2016
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical TrialsPanayiota Petrou, Yael Gothelf, Zohar Argov, et al.
Stem Cell Reports|October 25, 2016
Marked Differences in C9orf72 Methylation Status and Isoform Expression between C9/ALS Human Embryonic and Induced Pluripotent Stem CellsYaara Cohen-Hadad, Gheona Altarescu, Talia Eldar-Geva, et al.
Journal of Neurology|March 10, 2022
Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progressionErica Tavazzi, Sebastian Daberdaku, Alessandro Zandonà, et al.
Science Advances|May 29, 2024
DNMT3B splicing dysregulation mediated by SMCHD1 loss contributes to DUX4 overexpression and FSHD pathogenesisEden Engal, Aveksha Sharma, Uria Aviel, et al.
Journal of Translational Medicine|February 15, 2023
Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial resultsMarc Gotkine, Yoseph Caraco, Yossef Lerner, et al.
Neurobiology of Aging|July 17, 2021
A recessive S174X mutation in Optineurin causes amyotrophic lateral sclerosis through a loss of function via allele-specific nonsense-mediated decayMarc Gotkine, Martina de Majo, Chun Hao Wong, et al.
Neurology. Genetics|May 21, 2021
Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher DiseaseLais M Oliveira, Tara Rastin, Graeme A M Nimmo, et al.
Brain : a Journal of Neurology|January 31, 2023
SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegiaSiddharth Srivastava, Hagar Mor Shaked, Kenneth Gable, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Biomed Research International|January 24, 2014
Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) miceMarc Gotkine, Gotkine Marc, Leah Rozenstein, et al.
Muscle & Nerve|December 12, 2013
Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapyPanayiota Petrou, Avizohar Argov, Vanda A Lennon, et al.
JAMA Neurology|January 12, 2016
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical TrialsPanayiota Petrou, Yael Gothelf, Zohar Argov, et al.
Stem Cell Reports|October 25, 2016
Marked Differences in C9orf72 Methylation Status and Isoform Expression between C9/ALS Human Embryonic and Induced Pluripotent Stem CellsYaara Cohen-Hadad, Gheona Altarescu, Talia Eldar-Geva, et al.
Journal of Neurology|March 10, 2022
Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progressionErica Tavazzi, Sebastian Daberdaku, Alessandro Zandonà, et al.
Science Advances|May 29, 2024
DNMT3B splicing dysregulation mediated by SMCHD1 loss contributes to DUX4 overexpression and FSHD pathogenesisEden Engal, Aveksha Sharma, Uria Aviel, et al.
Journal of Translational Medicine|February 15, 2023
Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial resultsMarc Gotkine, Yoseph Caraco, Yossef Lerner, et al.
Neurobiology of Aging|July 17, 2021
A recessive S174X mutation in Optineurin causes amyotrophic lateral sclerosis through a loss of function via allele-specific nonsense-mediated decayMarc Gotkine, Martina de Majo, Chun Hao Wong, et al.
Neurology. Genetics|May 21, 2021
Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher DiseaseLais M Oliveira, Tara Rastin, Graeme A M Nimmo, et al.
Brain : a Journal of Neurology|January 31, 2023
SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegiaSiddharth Srivastava, Hagar Mor Shaked, Kenneth Gable, et al.
Pageof 8